Ascelia Pharma; Positive clarity for the pivotal SPARKLE study - Redeye

Ascelia's pivotal SPARKLE study will not be completed with 80 patients (earlier up to 200) and we can expect completion by February-March (earlier end 2022) with top-line read out in mid-2023. This is mainly positive as we welcome the clarity and especially as the main reason for the patient reduction is that a new review demonstrates a "strong and statistically significant effect".

Länk till analysen i sin helhet: https://www.redeye.se/research/867701/ascelia-pharma-positive-clarity-for-the-pivotal-sparkle-study?utm_source=finwire&utm_medium=RSS